MGNX News and Press, MacroGenics Inc. From 04/29/21

MacroGenics, Inc. (MGNX) Q1 2021 Earnings Conference Call April 29, 2021 16:30 ET Company Participants Anna Krassowska - Investor Relations Scott Koenig - President & Chief Executive Officer Jim Karrels - Senior Vice President & Chief Financial Officer Conference Call Participants Jon...

MacroGenics (MGNX): Q1 GAAP EPS of -$0.90 misses by $0.30.Revenue of $16.88M (+23.4% Y/Y) misses by $9.32M.Press Release For further details see: MacroGenics EPS misses by $0.30, misses on revenue

MARGENZA™ launched in mid-March Upcoming poster presentation of MGC018 initial Phase 1 clinical data at ASCO Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md., April 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX),...

MacroGenics Inc. (NASDAQ:MGNX) traded at a new 52-week high today of $35.00. This new high was reached on below average trading volume as 370,000 shares traded hands, while the average 30-day volume is approximately 767,000 shares. MacroGenics Inc. (NASDAQ:MGNX) is currently priced 3.5% ...

ROCKVILLE, MD, April 19, 2021 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its fi...

MacroGenics (MGNX) and Alligator Bioscience (ALLGF) have collaborated to expand latter's proprietary patient specific immunotherapy Neo-X-Prime with MGNX's DART and TRIDENT multi-specific platforms against two undisclosed targets. Under the collaboration, which covers activities fro...

ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American Associa...

MacroGenics is a $1.75bn market cap biotech that's pushing the boundaries of drug development. The company has >8 different molecules in development thanks to a platform that generates bispecific, Fc-engineered, dual antibody targeting immuno-oncology assets. Margenza has won a...

Bristol Myers Squibb ([[BMY]] -0.2%) trades marginally lower in the morning hours despite the pre-market announcement of the positive results from relatlimab and Opdivo combo in a Phase 2/3 trial in previously untreated metastatic or unresectable melanoma.Relatlimab is an anti-LAG-3 anti...

Pieris Pharmaceuticals PIRS +46% on collaboration with Seagen.Houston Wire & Cable Company HWCC +41% on being acquired by OmniCable for $5.30 per share.Cellect Biotechnology APOP +41% on a definitive merger agreement with Quoin Pharmaceuticals.Immutep Limited...